Alexander VosChief Executive Officer
Alexander Vos has 25 years of leadership experience in the biotech industry. After five years at the pharmaceutical practice of McKinsey&Co, he continued at Genzyme Therapeutics Europe, holding several executive positions, including global responsibility for the Genzyme/Pharming JV to develop an ERT for Pompe’s Disease. From 2000 to 2004, Mr. Vos served as CEO of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. Subsequently he joined PAION AG, a publicly listed, clinical stage biopharma company based in Aachen (Germany) as a Member of the Management Board (“Vorstand”), deputy-CEO and COO. In 2010 he became the CEO of PharmaCell BV and helped turn it into the leading European CMO for cell and gene therapy. PharmaCell was sold to Lonza in May 2017 creating a successful exit for investors. He currently serves on the Board of Directors of several privately held biotechnology companies. Mr. Vos holds a MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University.
Pieter ReitsmaChief Scientific Officer and Founder
Emeritus professor Pieter Reitsma is a leading expert in coagulation and previous head of the department of Thrombosis and Hemostasis at LUMC. Pieter Reitsma has always worked at the interface of fundamental science and clinical applications. He is a translational scientist ‘avant la lettre’ who is among the very few to have brought drugs and diagnostic tests to the clinic. In the early stage of his career he did the experimental animal and in vitro work which was needed to bring the bisphosphonate APD to the clinic to successfully treat patients with destructive bone disease. Later he turned to the field of Hemostasis and Thrombosis where he made seminal contributions that made him world leader in the genetics of Hemostasis and Thrombosis. The test for factor V Leiden that he co-discovered is considered to be the most commonly performed genetic test in the world.
MaartjeChief Operating Officer
Maartje brings approximately 15 years of experience in the development of biologic therapeutics. She previously held R&D positions at AbbVie (US) and Abbott (the Netherlands), as well as at Crucell NV in the Netherlands, leading process development and manufacturing efforts. Maartje’s experience includes pre-clinical development up to and including Phase III/ commercial launch, including the preparation of regulatory filings from initial IND/IMPDs to BLA/MAA. Maartje is Senior Consultant at Venn Life Sciences, where she provides strategic, tactical and operational input to emerging and established biopharma. Maartje has a Msc. in Biotechnology from the University of Wageningen and a Ph.D. from Leiden University.